Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts-Reference-Cited by-同舟云学术

Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts

Published:2016-12 Issue:1 Volume:18 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Cardwell Chris R.,Pottegård Anton,Vaes Evelien,Garmo Hans,Murray Liam J.,Brown Chris,Vissers Pauline A. J.,O’Rorke Michael,Visvanathan Kala,Cronin-Fenton Deirdre,De Schutter Harlinde,Lambe Mats,Powe Des G.,van Herk-Sukel Myrthe P. P.,Gavin Anna,Friis Søren,Sharp Linda,Bennett Kathleen

Funder

Cancer Research UK

Public Health Agency

Health Research Board

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-016-0782-5.pdf

Reference43 articles.

1. Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacopther. 2001;11:2599–607.

2. Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol. 2012;4:113–25.

3. Powe DG, Voss MJ, Habashy HO, et al. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat. 2011;130:457–63.